FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

CODE KENNETH REAY
2. Issuer Name and Ticker or Trading Symbol

BIOLARGO, INC. [ BLGO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Science Officer
(Last)          (First)          (Middle)

14921 CHESTNUT ST.
3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2019
(Street)

WESTMINSTER, CA 92683
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock  9/30/2019    A    35080  A $0.315 (1) 23389001  D (2)  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Shares received in exchange for a reduction in $11,050.28 owed by Registrant to Reporting Person for salary and unreimbursed business expenses.
(2)  Aggregate total shares includes 22,139,012 shares owned indirectly by Reporting Person through a wholly owned corporation.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CODE KENNETH REAY
14921 CHESTNUT ST.
WESTMINSTER, CA 92683
X X Chief Science Officer

Signatures
/s/ John R. Browning, Attorney-in-Fact 10/2/2019
**Signature of Reporting Person Date


BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more BioLargo (QB) Charts.
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more BioLargo (QB) Charts.

Biolargo, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Form D - Notice of Exempt Offering of Securities
Wednesday 24 January 2024 (3 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 23 January 2024 (3 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 11 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Saturday 6 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 21 November 2023 (5 months ago) • Edgar (US Regulatory)
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 15 November 2023 (6 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 5 October 2023 (7 months ago) • Edgar (US Regulatory)